SUMGEN
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SUMGEN - overview
Established
2015
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Founded in 2015 and based in Hangzhou, China, Hangzhou Sumgen Biotech Co. , Ltd. trading as SUMGEN, is a biopharmaceutical company dedicated to the creation and commercialization of antibody therapeutics for cancer and other serious diseases. In December 2025, SUMGEN closed Series C funding from new investors Oriental Fortune Capital, Chime Biologics Limited Qijian Foundation.
The company develops an integrated process covering drug discovery, manufacturing, and clinical development. The company's main product pipeline is focused on broad immuno-oncology targets, with SG001, SG301, SG404, and SG12473 projects in the clinical study stage. It also offers a technology platform for antibody discovery for bispecific antibodies and deployed abundant innovative pipelines in the tumor field. The company generates revenue by doing R&D, and providing innovative antibody drugs for the treatment of major diseases such as cancer and other related products.
The Series C funding raised in December 2025 will be used to advance the clinical development and industrialization of its pipeline drugs, further solidifying its innovative position in the field of therapeutic antibodies.
Current Investors
Hankang Capital, China National Biotec Group, Harmony Venture
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals
Website
www.sumgenbio.com
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.